The findings strongly suggested that p21WAF1/CIP1 gene expression might be used as a key prognostic biomarker for breast cancer, allowing therapy options to be adjusted more appropriately for individual cancer patients [77]. This evidence concerns the gene CDKN1A and breast carcinoma.